The traditionally busy spring selling season is bogged down by high interest rates, inflated prices and tight supply.
Continue readingCategory Archives: Uncategorized
Vice Media declares Fortress Investment Group the winning bidder in bankruptcy sale
Vice Media will be acquired by Fortress Investment Group and other creditors for $225 million.
Continue readingKey Boeing supplier stops production at Wichita plant after workers vote to strike
Spirit AeroSystems makes fuselages for Boeing’s 737 Max and parts for other aerospace manufacturers.
Continue readingZaslav contacted Scorsese and Spielberg to ease fears around TCM layoffs
Warner Bros. Discovery CEO David Zaslav spoke with top filmmakers Martin Scorsese and Steven Spielberg to calm fears as layoffs hit Turner Classic Movies
Continue readingUnited to send flight disruption vouchers to travelers’ phones
United said its new app update will make it easier for customers to rebook, track bags and retrieve vouchers for hotels and meals during flight […]
Continue readingOlive Garden parent earnings beat estimates, fueled by strong LongHorn Steakhouse sales
Darden’s Olive Garden had a weaker-than-expected quarter, but LongHorn Steakhouse reported strong same-store sales growth.
Continue readingBoycotts rarely work — but anti-LGBTQ+ backlash is forcing companies into tough choices
The boycott of Bud Light is having a major effect on its sales, while the wave of anti-LGBTQ+ backlash is also affecting Target and Starbucks.
Continue readingOverstock.com wins auction for Bed Bath & Beyond’s intellectual property, digital assets
E-commerce discounter Overstock.com will buy Bed Bath & Beyond’s intellectual property and digital assets for $21.5 million.
Continue readingPharmaceutical trade group sues Biden administration over Medicare drug price negotiations
PhRMA’s lawsuit is the fourth legal challenge to the law after separate suits from Merck, Bristol Myers Squibb and the U.S. Chamber of Commerce.
Continue readingCDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults 60 and older
The CDC panel’s recommendation moves the U.S. closer to making the respiratory syncytial virus shots from Pfizer and GSK available to seniors.
Continue reading